The role of gastric cancer patient-derived organoids in precision medicine: Clinicians' perspective
Details
Publication Year 2026-08-11,Volume 21,Issue #8,Page 103006
Journal Title
Stem Cell Reports
Publication Type
Research article
Abstract
Organoid technology holds great potential and hope for personalized treatment in gastric cancer (GC). To date, clinicians' views on this technology for precision oncology have not been reported despite these insights being invaluable to understanding how organoids may be effectively integrated into clinical practice. Hence, we explored clinicians' knowledge and perception of organoid research and its potential clinical utility in GC treatment. Clinicians believed that organoids would be most useful for guiding adjuvant treatment in patients who fail neoadjuvant therapy and emphasized the importance of obtaining results within 4-6 weeks of surgical resection. Clinicians also expressed concerns and suggestions related to current research methodologies and highlighted the ethical and political aspects of organoid-guided personalized medicine. Overall, most clinicians perceived the value in the use of organoids to guide personalized treatment in GC and provided important insights into how this approach could be best implemented in clinical practice in the future.
Publisher
Elsevier
Keywords
Humans; *Precision Medicine/methods; *Organoids/pathology; *Stomach Neoplasms/therapy/pathology; clinician perspective survey; gastric cancer; organoids; precision medicine
Department(s)
Surgical Oncology; Laboratory Research
Open Access at Publisher's Site
https://doi.org/10.1016/j.stemcr.2026.103006
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2026-08-06 02:27:25
Last Modified: 2026-09-14 05:56:13
An error has occurred. This application may no longer respond until reloaded. Reload 🗙